DM232 (unifiram) and DM235 (sunifiram) are potent cognition-enhancers, which are four order of magnitude more potent than piracetam. These compounds, although not showing affinity in binding studies for the most important central receptors or channels, are able to prevent amnesia induced by modulation of several neurotransmission systems. These compounds are able to increase the release of acetylcholine from rat cerebral cortex, and, as far as unifiram is concerned, to increase the amplitude of fEPSP in rat hippocampal slices. In vitro experiments, performed on hippocampal slices, also supported the hypothesis of a role of the AMPA receptors for the cognition-enhancing properties of unifiram and sunifiram.

Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition-enhancers / M. ROMANELLI; N. GALEOTTI; C. GHELARDINI; D. MANETTI; E. MARTINI; F. GUALTIERI. - In: CNS DRUG REVIEWS. - ISSN 1080-563X. - STAMPA. - 12:(2006), pp. 39-52. [10.1111/j.1527-3458.2006.00039.x]

Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition-enhancers

ROMANELLI, MARIA NOVELLA;GALEOTTI, NICOLETTA;GHELARDINI, CARLA;MANETTI, DINA;MARTINI, ELISABETTA;GUALTIERI, FULVIO
2006

Abstract

DM232 (unifiram) and DM235 (sunifiram) are potent cognition-enhancers, which are four order of magnitude more potent than piracetam. These compounds, although not showing affinity in binding studies for the most important central receptors or channels, are able to prevent amnesia induced by modulation of several neurotransmission systems. These compounds are able to increase the release of acetylcholine from rat cerebral cortex, and, as far as unifiram is concerned, to increase the amplitude of fEPSP in rat hippocampal slices. In vitro experiments, performed on hippocampal slices, also supported the hypothesis of a role of the AMPA receptors for the cognition-enhancing properties of unifiram and sunifiram.
2006
12
39
52
M. ROMANELLI; N. GALEOTTI; C. GHELARDINI; D. MANETTI; E. MARTINI; F. GUALTIERI
File in questo prodotto:
File Dimensione Formato  
104.DM232-235 CNS Drug rev 2006.pdf

accesso aperto

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Open Access
Dimensione 152.48 kB
Formato Adobe PDF
152.48 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/221744
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 16
social impact